Symbols / MLYS Stock $28.43 +9.22% Mineralys Therapeutics, Inc.
MLYS (Stock) Chart
Stock Fundamentals
|
|
|
|
|
|
About
Official websiteMineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. It is developing lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep apnea. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. Mineralys Therapeutics, Inc. was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
Ratings
Current target
$28.43
Low
$30.00
High
$56.00
Mean
$48.50
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-04-27 | init | TD Cowen | — → Buy | — |
| 2026-03-13 | main | B of A Securities | Buy → Buy | $51 |
| 2025-12-19 | main | Stifel | Buy → Buy | $52 |
| 2025-11-12 | main | HC Wainwright & Co. | Buy → Buy | $56 |
| 2025-11-11 | main | Wells Fargo | Overweight → Overweight | $55 |
| 2025-10-30 | main | HC Wainwright & Co. | Buy → Buy | $52 |
| 2025-09-11 | main | Wells Fargo | Overweight → Overweight | $50 |
| 2025-09-09 | main | Goldman Sachs | Buy → Buy | $52 |
| 2025-09-08 | reit | HC Wainwright & Co. | Buy → Buy | $42 |
| 2025-09-03 | main | Jefferies | Hold → Hold | $26 |
| 2025-08-28 | main | B of A Securities | Buy → Buy | $43 |
| 2025-08-13 | reit | HC Wainwright & Co. | Buy → Buy | $42 |
| 2025-06-17 | reit | HC Wainwright & Co. | Buy → Buy | $42 |
| 2025-06-11 | init | Jefferies | — → Hold | $15 |
| 2025-05-13 | reit | HC Wainwright & Co. | Buy → Buy | $42 |
| 2025-04-02 | main | HC Wainwright & Co. | Buy → Buy | $42 |
| 2025-03-10 | reit | HC Wainwright & Co. | Buy → Buy | $30 |
| 2025-02-24 | reit | Guggenheim | Buy → Buy | — |
| 2025-02-13 | main | Goldman Sachs | Buy → Buy | $24 |
| 2025-02-13 | reit | HC Wainwright & Co. | Buy → Buy | $30 |
- Lorundrostat Phase 3 data in uncontrolled blood pressure, CKD going to ESH 2026 - Stock Titan Mon, 18 May 2026 20
- Mineralys Therapeutics (MLYS) Is Down 11.2% After Q1 Loss And Upcoming Phase 3 Lorundrostat Data - simplywall.st ue, 19 May 2026 09
- Mineralys Therapeutics Stock Surges on Trial Hopes - TipRanks Wed, 20 May 2026 14
- Mineralys CMO David Rodman sells $11,488 in shares - Investing.com ue, 19 May 2026 23
- Mineralys Therapeutics (MLYS) Appoints Jeffrey A. Munsie as Chief Legal Officer - Yahoo Finance Sun, 26 Apr 2026 07
- Mineralys (NASDAQ: MLYS) CMO exercises options and sells 417 pre-planned shares - Stock Titan ue, 19 May 2026 23
- Is Mineralys Therapeutics, Inc. (MLYS) A Good Stock To Buy Now? - Yahoo Finance Sun, 03 May 2026 07
- Mineralys: Buy Rating Reiterated on Superior Lorundrostat Profile vs. Baxfendy and Unchanged $42 Price Target - TipRanks Wed, 20 May 2026 09
- 417‑share proposed sale by Mineralys (NASDAQ: MLYS) via cashless exercise - Stock Titan Mon, 18 May 2026 20
- Congleton, Mineralys Therapeutics CEO, sells $421k in MLYS stock - Investing.com Wed, 15 Apr 2026 07
- Is Mineralys Therapeutics (MLYS) Pricing Reflect The Recent Share Price Pullback - Yahoo Finance Mon, 16 Feb 2026 08
- Two new Mineralys hires get stock options and RSUs under Nasdaq rule - Stock Titan ue, 05 May 2026 07
- Mineralys fireside chat at Bank of America conference streams May 12 - Stock Titan ue, 05 May 2026 07
- Mineralys (NASDAQ: MLYS) CMO exercises options, sells 22,575 shares in 10b5-1 plan - Stock Titan hu, 14 May 2026 01
- FDA accepts Mineralys hypertension drug filing; Dec. 22 decision date - Stock Titan Wed, 06 May 2026 07
Insider Transactions
Financials
Statement View
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Expense |
|
170.60
-11.33%
|
192.40
+127.27%
|
84.66
+168.93%
|
31.48
|
| Research And Development |
|
132.01
-21.69%
|
168.58
+139.59%
|
70.36
+168.04%
|
26.25
|
| Selling General And Administration |
|
38.59
+62.01%
|
23.82
+66.63%
|
14.30
+173.40%
|
5.23
|
| General And Administrative Expense |
|
38.59
+62.01%
|
23.82
+66.63%
|
14.30
+173.40%
|
5.23
|
| Other Gand A |
|
38.59
+62.01%
|
23.82
+66.63%
|
14.30
+173.40%
|
5.23
|
| Total Expenses |
|
170.60
-11.33%
|
192.40
+127.27%
|
84.66
+168.93%
|
31.48
|
| Operating Income |
|
-170.60
+11.33%
|
-192.40
-127.27%
|
-84.66
-168.93%
|
-31.48
|
| Total Operating Income As Reported |
|
-170.60
+11.33%
|
-192.40
-127.27%
|
-84.66
-168.93%
|
-31.48
|
| EBITDA |
|
-170.54
+11.34%
|
-192.36
-127.22%
|
-84.66
-168.93%
|
-31.48
|
| Normalized EBITDA |
|
-170.54
+11.34%
|
-192.36
-127.22%
|
-84.66
-168.93%
|
-31.48
|
| Reconciled Depreciation |
|
0.06
+37.21%
|
0.04
|
0.00
|
—
|
| EBIT |
|
-170.60
+11.33%
|
-192.40
-127.27%
|
-84.66
-168.93%
|
-31.48
|
| Total Unusual Items |
|
—
|
—
|
—
|
—
|
| Total Unusual Items Excluding Goodwill |
|
—
|
—
|
—
|
—
|
| Net Income |
|
-154.65
+13.02%
|
-177.81
-147.31%
|
-71.90
-141.28%
|
-29.80
|
| Pretax Income |
|
-154.65
+13.02%
|
-177.81
-147.31%
|
-71.90
-141.28%
|
-29.80
|
| Net Non Operating Interest Income Expense |
|
15.95
+9.36%
|
14.59
+14.36%
|
12.76
+661.10%
|
1.68
|
| Interest Expense Non Operating |
|
—
|
—
|
—
|
—
|
| Net Interest Income |
|
15.95
+9.36%
|
14.59
+14.36%
|
12.76
+661.10%
|
1.68
|
| Interest Expense |
|
—
|
—
|
—
|
—
|
| Interest Income Non Operating |
|
15.95
+9.36%
|
14.59
+14.36%
|
12.76
+661.10%
|
1.68
|
| Interest Income |
|
15.95
+9.36%
|
14.59
+14.36%
|
12.76
+661.10%
|
1.68
|
| Other Income Expense |
|
—
|
0.01
+66.67%
|
0.00
-25.00%
|
0.00
|
| Other Non Operating Income Expenses |
|
—
|
0.01
+66.67%
|
0.00
-25.00%
|
0.00
|
| Gain On Sale Of Security |
|
—
|
—
|
—
|
—
|
| Tax Rate For Calcs |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-154.65
+13.02%
|
-177.81
-147.31%
|
-71.90
-141.28%
|
-29.80
|
| Net Income From Continuing Operation Net Minority Interest |
|
-154.65
+13.02%
|
-177.81
-147.31%
|
-71.90
-141.28%
|
-29.80
|
| Net Income From Continuing And Discontinued Operation |
|
-154.65
+13.02%
|
-177.81
-147.31%
|
-71.90
-141.28%
|
-29.80
|
| Net Income Continuous Operations |
|
-154.65
+13.02%
|
-177.81
-147.31%
|
-71.90
-141.28%
|
-29.80
|
| Normalized Income |
|
-154.65
+13.02%
|
-177.81
-147.31%
|
-71.90
-141.28%
|
-29.80
|
| Net Income Common Stockholders |
|
-154.65
+13.02%
|
-177.81
-147.31%
|
-71.90
-141.28%
|
-29.80
|
| Otherunder Preferred Stock Dividend |
|
—
|
—
|
—
|
—
|
| Diluted EPS |
|
—
|
-3.66
-83.92%
|
-1.99
-160.82%
|
-0.76
|
| Basic EPS |
|
—
|
-3.66
-83.92%
|
-1.99
-160.82%
|
-0.76
|
| Basic Average Shares |
|
—
|
48.54
+34.13%
|
36.19
-7.34%
|
39.06
|
| Diluted Average Shares |
|
—
|
48.54
+34.13%
|
36.19
-7.34%
|
39.06
|
| Diluted NI Availto Com Stockholders |
|
-154.65
+13.02%
|
-177.81
-147.31%
|
-71.90
-141.28%
|
-29.80
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
661.81
+221.42%
|
205.90
-18.17%
|
251.64
+119.88%
|
114.44
|
| Current Assets |
|
661.39
+222.08%
|
205.35
-17.56%
|
249.10
+120.81%
|
112.81
|
| Cash Cash Equivalents And Short Term Investments |
|
656.63
+231.32%
|
198.19
-16.22%
|
236.57
+114.85%
|
110.11
|
| Cash And Cash Equivalents |
|
172.92
+51.56%
|
114.09
+131.40%
|
49.30
-43.78%
|
87.70
|
| Cash Equivalents |
|
171.89
+51.54%
|
113.43
+133.10%
|
48.66
-42.64%
|
84.83
|
| Cash Financial |
|
1.03
+55.12%
|
0.66
+3.27%
|
0.64
-77.61%
|
2.87
|
| Other Short Term Investments |
|
483.71
+475.19%
|
84.10
-55.09%
|
187.26
+735.66%
|
22.41
|
| Prepaid Assets |
|
—
|
—
|
—
|
—
|
| Other Current Assets |
|
4.75
-33.68%
|
7.16
-42.85%
|
12.54
+364.12%
|
2.70
|
| Total Non Current Assets |
|
0.42
-23.91%
|
0.55
-78.21%
|
2.53
+55.30%
|
1.63
|
| Net PPE |
|
0.04
-28.30%
|
0.05
|
0.00
|
—
|
| Investments And Advances |
|
—
|
0.00
-100.00%
|
2.48
|
0.00
|
| Other Investments |
|
—
|
0.00
-100.00%
|
2.48
|
0.00
|
| Non Current Deferred Assets |
|
—
|
—
|
0.05
-96.87%
|
1.63
|
| Other Non Current Assets |
|
0.38
-23.45%
|
0.50
+878.43%
|
0.05
|
—
|
| Total Liabilities Net Minority Interest |
|
15.11
+3.19%
|
14.65
+39.73%
|
10.48
-93.71%
|
166.71
|
| Current Liabilities |
|
15.11
+3.19%
|
14.65
+39.73%
|
10.48
+29.94%
|
8.07
|
| Payables And Accrued Expenses |
|
9.57
-13.48%
|
11.06
+24.55%
|
8.88
+20.01%
|
7.40
|
| Payables |
|
2.02
+321.09%
|
0.48
-20.30%
|
0.60
-68.48%
|
1.91
|
| Accounts Payable |
|
2.02
+321.09%
|
0.48
-20.30%
|
0.60
-68.48%
|
1.91
|
| Current Accrued Expenses |
|
7.56
-28.62%
|
10.59
+27.81%
|
8.28
+50.72%
|
5.50
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
5.54
+54.66%
|
3.58
+124.02%
|
1.60
+140.45%
|
0.67
|
| Total Non Current Liabilities Net Minority Interest |
|
0.00
|
0.00
|
0.00
-100.00%
|
158.64
|
| Preferred Securities Outside Stock Equity |
|
—
|
0.00
|
0.00
-100.00%
|
158.64
|
| Stockholders Equity |
|
646.69
+238.13%
|
191.26
-20.69%
|
241.15
+561.37%
|
-52.27
|
| Common Stock Equity |
|
646.69
+238.13%
|
191.26
-20.69%
|
241.15
+561.37%
|
-52.27
|
| Capital Stock |
|
0.01
+60.00%
|
0.01
+25.00%
|
0.00
+300.00%
|
0.00
|
| Common Stock |
|
0.01
+60.00%
|
0.01
+25.00%
|
0.00
+300.00%
|
0.00
|
| Preferred Stock |
|
—
|
—
|
—
|
—
|
| Share Issued |
|
81.54
+63.66%
|
49.82
+21.12%
|
41.13
+5.32%
|
39.06
|
| Ordinary Shares Number |
|
81.54
+63.66%
|
49.82
+21.12%
|
41.13
+5.32%
|
39.06
|
| Additional Paid In Capital |
|
1,103.85
+123.56%
|
493.77
+34.96%
|
365.86
+67651.48%
|
0.54
|
| Retained Earnings |
|
-457.17
-51.12%
|
-302.52
-142.58%
|
-124.71
-136.14%
|
-52.81
|
| Total Equity Gross Minority Interest |
|
646.69
+238.13%
|
191.26
-20.69%
|
241.15
+561.37%
|
-52.27
|
| Total Capitalization |
|
646.69
+238.13%
|
191.26
-20.69%
|
241.15
+561.37%
|
-52.27
|
| Working Capital |
|
646.27
+238.89%
|
190.71
-20.08%
|
238.62
+127.81%
|
104.74
|
| Invested Capital |
|
646.69
+238.13%
|
191.26
-20.69%
|
241.15
+561.37%
|
-52.27
|
| Net Tangible Assets |
|
646.69
+238.13%
|
191.26
-20.69%
|
241.15
+561.37%
|
-52.27
|
| Tangible Book Value |
|
646.69
+238.13%
|
191.26
-20.69%
|
241.15
+561.37%
|
-52.27
|
| Preferred Stock Equity |
|
—
|
—
|
—
|
—
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-142.42
+14.37%
|
-166.31
-104.89%
|
-81.17
-177.79%
|
-29.22
|
| Cash Flow From Continuing Operating Activities |
|
-142.42
+14.37%
|
-166.31
-104.89%
|
-81.17
-177.79%
|
-29.22
|
| Net Income From Continuing Operations |
|
-154.65
+13.02%
|
-177.81
-147.31%
|
-71.90
-141.28%
|
-29.80
|
| Depreciation Amortization Depletion |
|
0.06
+37.21%
|
0.04
|
0.00
|
—
|
| Depreciation And Amortization |
|
0.06
+37.21%
|
0.04
|
0.00
|
—
|
| Other Non Cash Items |
|
-9.88
-5.04%
|
-9.40
-37.00%
|
-6.87
-957.78%
|
-0.65
|
| Stock Based Compensation |
|
19.32
+70.47%
|
11.34
+124.03%
|
5.06
+1012.09%
|
0.46
|
| Unrealized Gain Loss On Investment Securities |
|
—
|
—
|
—
|
—
|
| Change In Working Capital |
|
2.73
-71.32%
|
9.52
+227.47%
|
-7.47
-1067.62%
|
0.77
|
| Change In Receivables |
|
-0.17
-139.15%
|
0.42
+219.44%
|
-0.35
|
0.00
|
| Change In Prepaid Assets |
|
2.47
-49.95%
|
4.93
+151.78%
|
-9.53
-325.45%
|
-2.24
|
| Change In Payables And Accrued Expense |
|
0.43
-89.74%
|
4.16
+72.38%
|
2.42
-19.82%
|
3.01
|
| Investing Cash Flow |
|
-389.75
-439.04%
|
114.96
+171.64%
|
-160.47
-637.50%
|
-21.76
|
| Cash Flow From Continuing Investing Activities |
|
-389.75
-439.04%
|
114.96
+171.64%
|
-160.47
-637.50%
|
-21.76
|
| Net PPE Purchase And Sale |
|
-0.01
+84.38%
|
-0.10
|
0.00
|
—
|
| Purchase Of PPE |
|
-0.01
+84.38%
|
-0.10
|
0.00
|
—
|
| Capital Expenditure |
|
-0.01
+84.38%
|
-0.10
|
—
|
—
|
| Net Investment Purchase And Sale |
|
-389.74
-438.74%
|
115.06
+171.70%
|
-160.47
-637.50%
|
-21.76
|
| Purchase Of Investment |
|
-814.74
-118.17%
|
-373.44
-7.32%
|
-347.97
-384.92%
|
-71.76
|
| Sale Of Investment |
|
425.00
-13.00%
|
488.50
+160.53%
|
187.50
+275.00%
|
50.00
|
| Financing Cash Flow |
|
591.00
+408.86%
|
116.14
-42.86%
|
203.25
+58.76%
|
128.02
|
| Cash Flow From Continuing Financing Activities |
|
591.00
+408.86%
|
116.14
-42.86%
|
203.25
+58.76%
|
128.02
|
| Net Issuance Payments Of Debt |
|
—
|
—
|
—
|
—
|
| Issuance Of Debt |
|
—
|
—
|
—
|
—
|
| Short Term Debt Issuance |
|
—
|
—
|
—
|
—
|
| Net Short Term Debt Issuance |
|
—
|
—
|
—
|
—
|
| Net Common Stock Issuance |
|
578.36
+398.33%
|
116.06
-42.83%
|
202.99
+12561.02%
|
-1.63
|
| Common Stock Payments |
|
—
|
—
|
—
|
-1.63
|
| Repurchase Of Capital Stock |
|
—
|
—
|
—
|
-1.63
|
| Proceeds From Stock Option Exercised |
|
13.03
+2415.25%
|
0.52
+100.78%
|
0.26
|
0.00
|
| Net Other Financing Charges |
|
-0.39
+10.11%
|
-0.43
|
—
|
-1.63
|
| Changes In Cash |
|
58.83
-9.19%
|
64.79
+268.73%
|
-38.40
-149.84%
|
77.04
|
| Beginning Cash Position |
|
114.09
+131.40%
|
49.30
-43.78%
|
87.70
+722.56%
|
10.66
|
| End Cash Position |
|
172.92
+51.56%
|
114.09
+131.40%
|
49.30
-43.78%
|
87.70
|
| Free Cash Flow |
|
-142.43
+14.41%
|
-166.41
-105.01%
|
-81.17
-177.79%
|
-29.22
|
| Common Stock Issuance |
|
578.36
+398.33%
|
116.06
-42.83%
|
202.99
|
—
|
| Issuance Of Capital Stock |
|
578.36
+398.33%
|
116.06
-42.83%
|
202.99
+56.57%
|
129.65
|
| Net Preferred Stock Issuance |
|
—
|
—
|
0.00
-100.00%
|
129.65
|
| Preferred Stock Issuance |
|
—
|
—
|
0.00
-100.00%
|
129.65
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 42026-05-19 View
- 42026-05-13 View
- 10-Q2026-05-06 View
- 8-K2026-05-06 View
- 42026-04-21 View
- 42026-04-15 View
- 42026-04-15 View
- 42026-04-13 View
- 42026-04-02 View
- 42026-04-02 View
- 42026-03-31 View
- 42026-03-17 View
- 42026-03-16 View
- 10-K2026-03-12 View
- 8-K2026-03-12 View
- 42026-03-10 View
- 8-K2026-03-09 View
- 42026-02-20 View
- 42026-02-20 View
- 42026-02-20 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|